Does single-dose psilocybin beat placebo for depression?
Yes, for at least two weeks. In a single-centre, double-blind, randomised, placebo-controlled trial of 52 adults with major depressive disorder, a single moderate dose of psilocybin (0.215 mg/kg body weight) given with psychological support lowered depression scores significantly more than placebo at 14 days, and 14 of 26 participants (54%) in the psilocybin group met MADRS remission criteria. This was the first placebo-controlled trial of psilocybin-assisted therapy in this condition, not a definitive one: the authors themselves call for larger, multi-centre trials with longer follow-up.
Psilocybin is a preferential serotonin 1A/2A receptor agonist, and in this trial it was paired with psychological support during preparation, the dosing day, and integration.
What the data show:
- Effectiveness (MADRS): an absolute decrease of 13.0 points from baseline, significantly larger than placebo (95% CI -15.0 to -1.3; Cohen’s d = 0.97; p = 0.0011)
- Effectiveness (BDI): an absolute decrease of 13.2 points, also significantly larger than placebo (95% CI -13.4 to -1.3; Cohen’s d = 0.67; p = 0.019)
- Remission: 14 of 26 (54%) participants in the psilocybin condition met MADRS remission criteria
- Study scope: 52 patients (26 psilocybin, 26 placebo) at a single centre, with seven in-person visits over three weeks and equal psychological support time in both arms
The trial, published in eClinicalMedicine, tested whether a single moderate dose of psilocybin with psychological support outperforms placebo in major depressive disorder over a two week window. It reports that it does, with no serious adverse events recorded.
Dr. Kumar’s Take
I have watched psilocybin research accumulate impressive symptom reductions in open-label and waiting-list designs, where expectancy does a great deal of work. This trial closes part of that gap: it is the first placebo-controlled study of psilocybin-assisted therapy in major depressive disorder, and it shows that the improvement cannot be attributed to the psychological support alone. The design choice I find most interesting is the dose. Earlier trials used low doses at or below 10 mg or high doses above 20 mg and skipped the middle. This one sat in the moderate range and still produced a large effect on MADRS, with tolerability the authors describe as favourable compared with studies using repeated and higher doses. That is the practical question for anyone thinking about eventual clinical use: how little drug can you give and still get the benefit. I would hold my enthusiasm at the level the data support. Fifty two people at one hospital in Zurich, followed to two weeks, is a starting point, not a verdict.
Study Snapshot
This was a randomised, double-blind, placebo-controlled, parallel-group trial at a single centre, the Psychiatric University Hospital Zurich, Switzerland. Its stated objective was to investigate the effect of a single moderate dose of psilocybin compared with placebo, with equal time spent in psychological support in both conditions, in patients with major depressive disorder. It was not designed to settle the question: the authors conclude that larger, multi-centric trials with longer follow-up periods are needed to inform further optimisation of this treatment paradigm. Its contribution is being the first placebo comparison, which lets the pharmacological effect be separated from the non-pharmacological therapeutic setting.
Results in Real Numbers
The trial enrolled 52 participants (26 psilocybin, 26 placebo) and ran between April 11th, 2019 and October 12th, 2021. Mean age was 37.6 years (SD 10.9) in the psilocybin group and 35.9 years (SD 9.80) in the placebo group; 16 participants (61.5%) in the psilocybin group and 17 (65.4%) in the placebo group were female. Baseline MADRS scores were 24.3 (SD 5.07) and 24.1 (SD 7.07), and baseline BDI scores were 26.9 (SD 6.70) and 25.8 (SD 9.59). Eligibility required a MADRS score between 10 and 40, an age of 20 to 60, no unstable somatic conditions, and credible absence of suicidal ideation. Participants on psychiatric medication had to discontinue it under psychiatric supervision for at least two weeks or five half-lives before dosing. Each participant attended seven in-person visits over three weeks, covering preparation, drug administration, and integration sessions. Prior psychedelic experience was uneven between the arms: 5 participants (19.2%) in the psilocybin group versus 11 (42.3%) in the placebo group.
Fourteen days after the intervention, the psilocybin condition showed an absolute decrease in symptom severity of 13.0 points on MADRS from baseline, significantly larger than the change in the placebo condition (95% CI -15.0 to -1.3; Cohen’s d = 0.97; p = 0.0011). On BDI, the decrease was 13.2 points, again significantly larger than placebo (95% CI -13.4 to -1.3; Cohen’s d = 0.67; p = 0.019). 14 of 26 participants (54%) in the psilocybin condition met the MADRS remission criteria.
On safety, no serious adverse events were recorded, and the treatment was well tolerated by all participants. The authors describe tolerability as favourable compared with previously conducted studies that used repeated and higher doses, while effect sizes for efficacy remained comparable. That comparison is the basis for their argument that dose regimens can be tuned toward a better ratio of efficacy to tolerability.
The trial was registered with ClinicalTrials.gov (NCT03715127) and funded by the Swiss National Science Foundation, crowdfunding, the Swiss Neuromatrix Foundation, and the Heffter Research Institute.
Who Benefits Most
The people studied here were adults aged 20 to 60 with a current depressive episode in the context of major depressive disorder, with moderate symptom severity by MADRS, no unstable somatic conditions, no psychosis spectrum or mania history in themselves or first-degree relatives, and no recent alcohol or drug dependence. They were not selected for treatment resistance, so this is evidence about major depressive disorder broadly rather than about patients who have already failed multiple antidepressants.
Participants also had to be able to stop psychiatric medication safely beforehand and to have a close relative available to bring them home after the dosing day. Those two requirements are easy to skim past and they exclude a real fraction of the patients I see. Anyone thinking about this treatment should read them as part of the intervention, not administrative fine print.
Safety, Limits, and Caveats
No serious adverse events occurred and every participant tolerated the treatment, but this was 52 people at one hospital followed to 14 days. Durability beyond two weeks was not established by this trial, and the authors are explicit that longer follow-up is needed.
Blinding is the structural weakness of all psychedelic research, since the drug produces effects a participant can recognise. A placebo comparator is a genuine improvement over open-label and waiting-list designs, and it is what allows the authors to say the improvement is not attributable to the therapeutic embedding alone. It does not eliminate the problem. The imbalance in prior psychedelic experience between the two arms is another reason to treat a single trial of this size as a signal rather than a settled result.
The intervention is also inseparable from its setting: supervised administration, a full dosing day, and structured preparation and integration sessions with psychological support. Nothing here supports psilocybin taken outside that structure.
Practical Takeaways
- This is the first placebo-controlled evidence for psilocybin-assisted therapy in major depressive disorder, which is a meaningful step up from open-label and waiting-list designs
- A single moderate dose of 0.215 mg/kg produced significantly larger symptom reduction than placebo at 14 days on both MADRS and BDI
- Just over half of the psilocybin group, 14 of 26, met MADRS remission criteria
- Psychological support across seven visits was part of the protocol in both arms, so it should be planned for as a component of treatment rather than an add-on
- Treat the two week endpoint as the limit of what this trial demonstrates, and watch for the larger multi-centre trials with longer follow-up that the authors say are needed
What This Means for Depression Treatment
Conventional antidepressants act mainly on monoaminergic neurotransmission, take weeks to months to show a response, and leave a substantial share of patients short of remission. That is the gap psilocybin research is aimed at, and a placebo-controlled result is the kind of evidence that gap requires.
What this trial adds specifically is that the moderate dose range works. Earlier trials clustered at low doses of 10 mg or less or high doses above 20 mg. Showing a large effect in the middle, with tolerability the authors rate favourably against higher and repeated dosing, is how a treatment moves from proof of concept toward a usable regimen. The next step belongs to larger, multi-centre trials with longer follow-up.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
Why is a placebo-controlled trial important for psilocybin research?
Because the earlier psilocybin trials in depression were an open-label study, a waiting-list controlled trial, and a comparison against an SSRI, none of which can separate the drug’s effect from the psychological support and setting around it. As the first placebo-controlled study in major depressive disorder, this trial demonstrates that the improvements seen previously cannot be attributed to the non-pharmacological therapeutic embedding alone.
How can you have a true placebo with psilocybin’s obvious effects?
This trial used a double-blind, placebo-controlled, parallel-group design with equal time spent in psychological support in both conditions. My honest view is that blinding is never complete with a substance whose acute effects a participant can perceive, and that is a limitation to hold in mind for every trial in this field, including this one.
Is single-dose psilocybin as effective as multiple doses?
This trial did not compare the two directly. What the authors report is that a single moderate dose produced effect sizes comparable to previous studies that used repeated and higher doses, with tolerability they describe as favourable, which is why they argue the data can inform better dose regimens.
Bottom Line
The first placebo-controlled, double-blind trial of single-dose psilocybin in major depressive disorder found that 0.215 mg/kg with psychological support reduced depressive symptoms significantly more than placebo at 14 days, with 54% of the psilocybin group meeting MADRS remission criteria and no serious adverse events. It is a 52 person, single-centre, two week result, and the authors are the first to say that larger multi-centre trials with longer follow-up are what comes next.
